Literature DB >> 8964275

Cost of refractory epilepsy in adults in the USA.

M I Murray1, M T Halpern, I E Leppik.   

Abstract

A cost of illness of refractory epilepsy was developed based on estimates supplied by an expert panel of physicians and a review of the current literature. The basic elements of model can be divided into two main components: direct and indirect costs. Direct costs include the medical resource utilization patterns associated with epilepsy care while the indirect costs represent lost productivity associated with the disease. The results of the analysis indicate that an estimated 24,578 incident cases of epilepsy incur a total of $318,582,669; while our prevalence estimates indicate that 335,167 individuals incur a total of $3,905,183,463, in a given year. Direct medical costs account for one-third of the total costs while indirect costs constitute the remaining two-thirds.

Entities:  

Mesh:

Year:  1996        PMID: 8964275     DOI: 10.1016/0920-1211(95)00090-9

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  14 in total

Review 1.  The costs of epilepsy and cost-based evaluations of anticonvulsants.

Authors:  W G Johnson
Journal:  Pharmacoeconomics       Date:  1997-10       Impact factor: 4.981

2.  Economic burden of epilepsy among the privately insured in the US.

Authors:  Jasmina I Ivanova; Howard G Birnbaum; Yohanne Kidolezi; Ying Qiu; David Mallett; Sue Caleo
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 3.  Cellular mechanisms underlying acquired epilepsy: the calcium hypothesis of the induction and maintainance of epilepsy.

Authors:  Robert J Delorenzo; David A Sun; Laxmikant S Deshpande
Journal:  Pharmacol Ther       Date:  2004-12-09       Impact factor: 12.310

4.  Cost-of-illness of epilepsy in Italy. Data from a multicentre observational study (Episcreen).

Authors:  P Berto; P Tinuper; S Viaggi
Journal:  Pharmacoeconomics       Date:  2000-02       Impact factor: 4.981

5.  The novel antiepileptic drug carisbamate (RWJ 333369) is effective in inhibiting spontaneous recurrent seizure discharges and blocking sustained repetitive firing in cultured hippocampal neurons.

Authors:  Laxmikant S Deshpande; Nisha Nagarkatti; Sompong Sombati; Robert J DeLorenzo
Journal:  Epilepsy Res       Date:  2008-03-18       Impact factor: 3.045

Review 6.  Cost of epilepsy: a systematic review.

Authors:  Adam Strzelczyk; Jens Peter Reese; Richard Dodel; Hajo M Hamer
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

Review 7.  Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options.

Authors:  Wolfgang Löscher; Heidrun Potschka; Sanjay M Sisodiya; Annamaria Vezzani
Journal:  Pharmacol Rev       Date:  2020-07       Impact factor: 25.468

8.  Cost of illness of hyponatremia in the United States.

Authors:  Audra Boscoe; Clark Paramore; Joseph G Verbalis
Journal:  Cost Eff Resour Alloc       Date:  2006-05-31

9.  Cost-effectiveness of surgery for drug-resistant temporal lobe epilepsy in the US.

Authors:  Shehryar R Sheikh; Michael W Kattan; Michael Steinmetz; Mendel E Singer; Belinda L Udeh; Lara Jehi
Journal:  Neurology       Date:  2020-07-08       Impact factor: 9.910

10.  Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study.

Authors:  Maria Geitona; Hara Kousoulakou; Markos Ollandezos; Kostas Athanasakis; Sotiria Papanicolaou; Ioannis Kyriopoulos
Journal:  Ann Gen Psychiatry       Date:  2008-08-28       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.